RxDoctor Payments Data

Matthew Frankel, MD

Internal Medicine · Philadelphia, PANPI 1750387791

Payments from drug & device makers

$41,526in general payments, 2019–2025

Across 252 payments — averaging $164.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$36K
  • Gilead$2K
  • Novo Nordisk$792
  • Merck$516
  • AstraZeneca$356
  • Johnson & Johnson$217
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$5,528100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,526 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$3,339
Medicare patients
13
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArexvyRsvpref3 Antigen/As01e/Pf3,626$1,073,609
ShingrixVaricella-Zoster Ge/As01b/Pf2,646$560,951
AbrysvoRsv Vacc, Pref A And Pref B/Pf578$176,097
BiktarvyBictegrav/Emtricit/Tenofov Ala11$71,570
Boostrix TdapDiphth,pertuss(Acell),tet Vac1,076$71,454
TwinrixHepatitis A And B Vaccine/Pf63$8,891
HavrixHepatitis A Virus Vaccine/Pf62$6,179
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf51$3,406
Typhim ViTyphoid Vi Polysacch Vaccine24$3,341
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$2,780
Rosuvastatin Calcium53$1,200
IpolPoliomyelitis Vaccine, Killed11$683
Metoprolol Succinate18$333
Atorvastatin Calcium20$277
Levothyroxine Sodium21$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix, Twinrix, Havrix$81$1,649,6316,397 claims
PfizerAbrysvo$179$176,097578 claims
GileadBiktarvy$1,608$71,57011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →